{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:54:29Z","timestamp":1785542069415,"version":"3.56.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.1001\/jamaoncol.2020.6353","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T23:33:33Z","timestamp":1608334413000},"page":"246","source":"Crossref","is-referenced-by-count":63,"title":["Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Catherine H.","family":"Van Poznak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[{"name":"SWOG Cancer Research Network Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Darke","sequence":"additional","affiliation":[{"name":"SWOG Cancer Research Network Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moinpour","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bagramian","sequence":"additional","affiliation":[{"name":"School of Dentistry, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Schubert","sequence":"additional","affiliation":[{"name":"University of Washington School of Dentistry, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Kathryn","family":"Hansen","sequence":"additional","affiliation":[{"name":"Clinical Program Specialists, Legacy Good Samaritan Hospital, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Floyd","sequence":"additional","affiliation":[{"name":"Heartland NCORP (National Cancer Institute Community Oncology Research Program)\/Cancer Care Specialists of Illinois, Swansea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker R.","family":"Dakhil","sequence":"additional","affiliation":[{"name":"Wichita NCORP\/Cancer Center of Kansas, Wichita"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danika L.","family":"Lew","sequence":"additional","affiliation":[{"name":"SWOG Cancer Research Network Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James Lloyd","family":"Wade","sequence":"additional","affiliation":[{"name":"Cancer Care Specialists of Illinois, Decatur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Fisch","sequence":"additional","affiliation":[{"name":"Department of General Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gralow","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Cancer Care Alliance, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"35","key":"coi200097r1","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology\u2013Cancer Care Ontario focused guideline update.","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi200097r2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update.","volume":"36","author":"Anderson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi200097r3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.clon.2013.03.003","article-title":"Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents.","volume":"25","author":"Poon","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"coi200097r4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"9596","key":"coi200097r6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"coi200097r7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1056\/NEJM199403033300902","article-title":"Pain and its treatment in outpatients with metastatic cancer.","volume":"330","author":"Cleeland","year":"1994","journal-title":"N Engl J Med"},{"issue":"35","key":"coi200097r8","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi200097r9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates.","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"coi200097r10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates.","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"key":"coi200097r14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J Royal Stat Soc Ser B"},{"issue":"4","key":"coi200097r15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks.","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"issue":"4","key":"coi200097r16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.","volume":"102","author":"Ruggiero","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"2","key":"coi200097r17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006.","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"coi200097r19","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update.","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"issue":"25","key":"coi200097r20","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline.","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi200097r21","first-page":"2477","article-title":"Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.","volume":"34","author":"DE Iuliis","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"coi200097r22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"coi200097r23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"coi200097r24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial.","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"coi200097r25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial.","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"coi200097r26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"key":"coi200097r11","volume-title":"Event History and Survival Analysis.","author":"Allison","edition":"2nd ed"},{"key":"coi200097r12","doi-asserted-by":"crossref","DOI":"10.1002\/9780470870709","volume-title":"Competing Risks: A Practical Perspective","author":"Pintilie","year":"2006"},{"key":"coi200097r5","unstructured":"Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases. Clinicaltrials.gov identifier: NCT00874211. Updated July 5, 2019. Accessed November 10, 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00874211"},{"key":"coi200097r13","unstructured":"Allison? PD. For causal analysis of competing risks, don\u2019t use Fine & Gray\u2019s subdistribution method. Published March 24, 2018. Accessed November 10, 2020. https:\/\/statisticalhorizons.com\/for-causal-analysis-of-competing-risks"},{"key":"coi200097r18","unstructured":"Center for Disease Control and Prevention. Oral and dental health. Updated October 30, 2020. Accessed April 20, 2020. https:\/\/www.cdc.gov\/nchs\/fastats\/dental.htm"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2773839\/jamaoncology_van_poznak_2020_oi_200097_1613590894.0333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:08:07Z","timestamp":1724080087000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2773839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.6353","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}